Baical Skullcap (Scutellaria baicalensis)

Baical Skullcap (Scutellaria baicalensis) is a root herb in Traditional Chinese Medicine whose primary bioactive flavonoids — baicalin, baicalein, and wogonin — drive its anti-inflammatory and immune-modulating effects. These compounds inhibit NF-κB signaling, suppress pro-inflammatory cytokines, and modulate Th1/Th2 immune balance, underpinning its hepatoprotective and anti-allergic properties.

Origin & History

Baical skullcap (Scutellaria baicalensis Georgi) is a flowering plant in the Lamiaceae family native to East Asia, with the root serving as the primary medicinal component. The herb is traditionally extracted using solvent-based methods to isolate its flavonoid constituents, producing more than 40 flavonoids including baicalin, baicalein, wogonin, and wogonoside as the major bioactive compounds.

Historical & Cultural Context

Baical skullcap has been widely used in traditional Chinese, Japanese, and Korean medicine for centuries to treat inflammation, allergy, and bacterial and viral infections. In Chinese medicine specifically, the root has been used for psychiatric disorders, representing a foundational component of East Asian herbal pharmacopeias.

Health Benefits

• Immune modulation: Compounds inhibit IL-4 production dose-dependently and decrease interferon gamma, suppressing Th2-dominant allergic responses (animal studies)
• Anti-inflammatory effects: Reduces liver enzymes AST and ALT, demonstrating hepatoprotective properties (preclinical evidence)
• Anti-cancer potential: Wogonin causes G1 cell cycle arrest while baicalin/baicalein cause G2/M accumulation in tumor cells (in vitro studies)
• Allergy management: Extract at 25mg/kg reduced ovalbumin-induced immune responses in animal models
• Liver protection: Baicalin increases TNF-α and IL-6, suggesting potential in liver regeneration after injury (animal studies)

How It Works

Baicalin and baicalein inhibit NF-κB nuclear translocation, reducing downstream transcription of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. Wogonin selectively suppresses IL-4 production in Th2 cells dose-dependently while decreasing interferon-gamma, shifting immune responses away from Th2-dominant allergic phenotypes. Additionally, baicalein inhibits 5-lipoxygenase (5-LOX) and cyclooxygenase-2 (COX-2) enzyme activity, blocking arachidonic acid conversion to pro-inflammatory leukotrienes and prostaglandins.

Scientific Research

The available research consists primarily of preclinical studies including in vitro cell-based experiments and animal models. No human clinical trials, randomized controlled trials (RCTs), or meta-analyses with PubMed identifiers were provided in the research dossier. Current evidence is limited to laboratory and animal research examining immune modulation, anti-cancer, and hepatoprotective effects.

Clinical Summary

Most available evidence for Baical Skullcap derives from in vitro cell studies and rodent models rather than robust human clinical trials, limiting direct extrapolation to clinical practice. Preclinical studies demonstrate significant reductions in liver enzymes AST and ALT following baicalin administration in chemically induced hepatotoxicity models, suggesting hepatoprotective potential. A limited number of small human studies have examined Scutellaria baicalensis in combination herbal formulas (e.g., Chinese patent medicines), making it difficult to isolate the single-ingredient effect. Overall, the evidence base is promising but preliminary, and large-scale randomized controlled trials in humans are lacking.

Nutritional Profile

Baical Skullcap (Scutellaria baicalensis) root is not consumed as a macronutrient source but contains a dense array of bioactive flavonoids and polyphenols. Primary bioactive compounds include: Baicalin (baicalein-7-glucuronide) at 10–15% dry weight of root, making it the most abundant constituent; Baicalein (aglycone form) at approximately 1–3% dry weight; Wogonin at 1–2% dry weight; Wogonoside (wogonin-7-glucuronide) at 0.5–1.5% dry weight; Oroxylin A and its glucuronide at trace to 0.5% dry weight; Scutellarein and scutellarein glycosides at trace levels. Secondary phytochemicals include iridoids, sterols (beta-sitosterol), and amino acids including gamma-aminobutyric acid (GABA) precursors. Mineral content of the dried root includes modest calcium (~4–6 mg/g dry weight), potassium, and iron, though these are not clinically significant at typical supplemental doses (3–9 g dried root/day or standardized extracts of 400–500 mg). Bioavailability notes: Baicalin undergoes hydrolysis by intestinal and gut-microbial beta-glucuronidases to the more bioavailable aglycone baicalein before absorption; peak plasma concentrations of baicalein occur approximately 1–2 hours post-oral ingestion. Wogonin has moderate oral bioavailability enhanced by lipid co-administration. Standardized extracts are typically normalized to 35–85% total flavonoids (as baicalin).

Preparation & Dosage

In animal studies, skullcap extract was administered at 25 mg/kg body weight orally for 16 days, while isolated wogonin was given at 1 mg/kg body weight. The butanol fraction contains approximately 13.38% ± 0.07% total polyphenol content. No standardized human dosage recommendations are available from clinical trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Green tea extract, Milk thistle, Turmeric, Quercetin, Resveratrol

Safety & Interactions

Baical Skullcap is generally considered well-tolerated at typical supplemental doses (200–500 mg standardized extract daily), but hepatotoxicity cases have been reported with products adulterated by Teucrium species mislabeled as skullcap. It may potentiate the effects of anticoagulants such as warfarin by inhibiting CYP2C9 enzyme activity, and caution is warranted when co-administering with immunosuppressant drugs given its immune-modulating activity. Animal studies suggest possible uterotonic effects, making it contraindicated during pregnancy. Individuals with autoimmune conditions should consult a healthcare provider before use due to its cytokine-modulating properties.